Drake ex rel. J.D. v. Allergan, Inc., 111 F. Supp. 3d 562

Background

J.D., a child with cerebral palsy, received off-label Botox injections in 2010 and 2012 for lower-limb spasticity; after the May 2012 injection he developed seizures and was later diagnosed with epilepsy.
Plaintiffs (J.D. through parents Kevin and Lori Drake) sued Allergan alleging negligence and Vermont Consumer Fraud Act violations; jury found for Plaintiffs on negligence (including punitive damages) and for Allergan on the VCFA claim.
Trial evidence included expert medical causation testimony (Dr. Anna Hristova), Allergan internal documents and marketing materials, clinical trial and post‑marketing adverse event data, and studies suggesting higher-dose exposures and plausible biological mechanisms.
Allergan previously pled guilty (2010) to promoting Botox for off‑label pediatric spasticity (criminal misbranding plea for conduct in 2000–2005).
Jury awarded $2,778,881.35 in compensatory damages (including $2.5M to J.D.) and $4,000,000 in punitive damages; court denied Allergan’s renewed Rule 50 motion and motion to strike the causation expert, and denied a new trial under Rule 59.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Medical causation — did Botox cause J.D.’s seizure disorder?	Hristova: totality of epidemiology, clinical trials, post‑marketing reports, timing, biological plausibility show Botox was a substantial cause.	Allergan: evidence insufficient; key studies (e.g., Albavera‑Hernández) were discredited and causation not established.	Court: Evidence viewed in aggregate was sufficient for a reasonable jury to find causation; denied JMOL.
Negligent promotion / proximate cause — did Allergan’s promotion cause Dr. Benjamin to treat and dose J.D.?	Plaintiffs: Allergan’s sales contacts, sponsored literature, WE MOVE influence, and marketing to pediatric specialists substantially contributed to Dr. Benjamin’s use and higher dosing.	Allergan: Dr. Benjamin’s training and clinical judgment, not Allergan, drove treatment and dosing choices.	Court: Jury could reasonably find Allergan’s promotion was a substantial factor in Dr. Benjamin’s practice and dosing; proximate cause sustained.
Punitive damages — was there reprehensible conduct and malice?	Plaintiffs: Allergan promoted off‑label and higher doses despite safety signals, profited from higher dosing, and pled guilty to off‑label promotion; malice or conscious disregard can be inferred.	Allergan: evidence insufficient to show the level of culpability required for punitive damages.	Court: Evidence supported finding of outrageously reprehensible conduct and malice (or conscious, deliberate disregard of a known substantial risk); punitive award upheld.
Motion for new trial / JMOL procedural standard	N/A (Plaintiffs sought judgment incorporating verdict).	Allergan: alternative request for new trial under Rule 59 or JMOL under Rule 50 based on insufficient evidence/erroneous verdict.	Court: Exercising deference to jury credibility findings and weighing evidence with restraint, court denied new trial and JMOL.

Key Cases Cited

Cross v. New York City Transit Authority, 417 F.3d 241 (2d Cir.) (standard for Rule 50 review)
Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (U.S.) (expert admissibility framework)
Reeves v. Sanderson Plumbing Prod., 530 U.S. 133 (U.S.) (Rule 50 evidentiary inferences; credibility cannot be reassessed by court)
Milward v. Acuity Specialty Prods. Group, Inc., 639 F.3d 11 (1st Cir.) (permitting expert causation inference from totality of different bodies of evidence)
Zuchowicz v. United States, 140 F.3d 381 (2d Cir.) (temporal relationship can support causation)
State Farm Mut. Auto. Ins. Co. v. Campbell, 538 U.S. 408 (U.S.) (due‑process nexus limit on punitive evidence)
Fly Fish Vermont, Inc. v. Chapin Hill Estates, 187 A.3d 1167 (Vt.) (Vermont punitive‑damages framework and malice/recklessness standards)
DeYoung v. Ruggiero, 971 A.2d 627 (Vt.) (malice may be inferred from conduct to secure financial gain)
United States v. Caronia, 703 F.3d 149 (2d Cir.) (constitutional limits on prohibiting truthful off‑label promotion)